Galway: GAPP - Galway Antimicrobial Prescribing Policy / Guidelines (GAPP): Respiratory System

Antivirals Guidance for Treatment and Prophylaxis of Influenza

Detailed guidance on the use of antiviral agents for the treatment and prophylaxis of influenza is available on the HSE/HPSC website https://www.hpsc.ie/a-z/respiratory/influenza/seasonalinfluenza/guidance/antiviraltreatmentandprophylaxisguidance/Antivirals%20guidance%20for%20treatment%20guidance/Antiviraltreatmentandprophylaxisguidance/Antivirals%20guidance%20for%20treatment%20guidance/Antiviraltreatmentandprophylaxisguidance/Antivirals%20guidance%20for%20treatment%20guidance/Antiviraltreatmentandprophylaxisguidance/Antivirals%20guidance%20for%20treatment%20guidance/Antiviraltreatmentandprophylaxisguidance/Antivirals%20guidance%20for%20treatment%20guidance/Antiviraltreatmentandprophylaxisguidance/Antivirals%20guidance/Antiviraltreatmentandprophylaxisguidance/Antivirals%20guidance/Antiviraltreatmentandprophylaxisguidance/Antiviraltreatmentandpro

Antiviral treatment

- · Antiviral treatment is recommended as early as possible for any patient with suspected or confirmed influenza who is hospitalised due to influenza
- Any patient who, while in hospital for other indication, develops influenza, should be assessed for risk from influenza complications (as below).
 Antiviral treatment is recommended as early as possible for those at higher risk from influenza complications.

Higher risk from influenza complications includes :

- 1. Age 65 years and over
- 2. Pregnancy (including up to two weeks post-partum)
- 3. Children aged <2 years of age
- 4. Chronic respiratory disease including those on medication for asthma
- 5. Chronic heart, kidney, liver or neurological disease
- 6. Diabetes mellitus
- 7. Haemoglobinopathies
- 8. Immunosuppression (whether due to treatment or disease e.g. HIV)
- 9. Morbid obesity (BMI ≥ 40)
- 10. Those with any condition that can compromise respiratory function (e.g cognitive dysfunction, spinal cord injury, seizure disorder, or other neuromuscular disorder), especially those attending special schools/day centres.
- 11. Those with Down Syndrome
- 12. Persons with moderate to severe neurodevelopmental disorders such as cerebral palsy and intellectual disability
- 13. Residents of nursing homes or Residential Care Facilities
- 1 st line antiviral treatment is generally PO/NG Oseltamivir 75mg BD for adult patients with normal renal function but:
- Dose Adjustment is required in renal impairment.
- Alternative therapy with Zanamivir may be indicated for patients with severe immunocompromise please discuss with Microbiology/Infectious
 Diseases
- · Treatment duration is generally 5 days.

There is limited evidence to support treating for longer duration in those with severe influenza (e.g critically ill in ICU) and in severely immunosuppressed patients. Discussion with Microbiology/Infectious Diseases is recommended.

Antiviral prophylaxis

Chemoprophylaxis (generally PO/NG Oseltamivir) may be considered for people at higher risk from influenza complications (as above, 1 to 13) who have had recent close contact with a person with influenza. Details on use of Oseltamivir for prophylaxis of high risk contacts, including dose, duration and dose adjustment in renal impairment are to be found in the HPSC/ HSE guidance

Community Acquired Pneumonia

Community Acquired Pneumonia (CAP)

- 1. Community acquired pneumonia is defined as infiltrate on CXR or CT scan with compatible symptoms.
- 2. Antibiotics are NOT usually recommended for exacerbation of asthma or bronchitis with normal chest X-ray or aspiration with normal CXR.
- 3. Nursing home patients presenting with pneumonia should be treated as CAP as outlined below and NOT automatically treated with piperacillin/tazobactam **unless** history of antibiotic resistant organisms or within 14 days of discharge from hospital.
- 4. The CURB-65 score, in conjunction with clinical judgement, is a severity assessment tool for Community Acquired Pneumonia.
- 5. Laboratory testing for respiratory viruses should be considered, including COVID-19, and, during relevant season, influenza and Respiratory Syncytial Virus (RSV). Appropriate treatment for COVID-19 or influenza should be initiated if positive.

Galway: GAPP - Galway Antimicrobial Prescribing Policy / Guidelines (GAPP) - Last Updated: Nov. 7, 2024, 11:53 a.r.	n., printed: Nov. 23, 2024
11:09 a.m.	

page 1 of 4

Culture sputum and blood if severe infection **OR** risk factors for MRSA or Pseudomonas infections:

- ICU admission
- Hospitalised and/or IV antibiotics within past 90 days
- Previous Infection with MRSA or Pseudomonas
- 7. Give antibiotics as soon as possible, within 4 hours of presentation in the Emergency Department.

Infection	mmunity Acquired Pneum 1 1 st Line Antibiotics	Penicillin allergy:		Penicillin allergy:	Comment
ouon	. Line Antibiotics	. Chiomin anergy.		. Cilionini aliergy.	- Commont
		delayed onset non-seve	re reaction	immediate or severe delayed reaction	
		See penicillin hypersensit	ivity section for further in	formation	
community	Mild CURB-65 Score 0 o	r 1			•
cquired	Amoxicillin PO 1g every	Doxycycline PO 100mg e	very 12 hours		Duration
	8 hours	Avoid Dovernating in proc	nanay or broad fooding	Discuss with Microbiology	
including	In younger patients Add	or Infectious Diseases.	mancy of breast-feeding	. Discuss with Microbiology	5 days
urcing home	atypical cover with	of fillections Diseases.			
atients	atypical cover with				(provided afebrile and
	Clarithromycin PO				clinically stable for 48
	500mg every 12 hours				hours. Otherwise 7 da
vithin 14 days	Moderate <u>CURB-65</u> Sco	re 2			
	Non-smokers with no	Levofloxacin PO (IV if NP	O) 500mg every 12 hour	S	
	co-morbidities				
oo noto on				Discuss with Micro/ID.	
ADDO '	Amoxicillin PO/IV 1g	Caution if risks for prolone	ged QT interval		
<u>IIDINO</u>	every 8 hours				
Signs and	+				
symptoms of					Duration
	Clarithromycin PO (IV if				
	NPO) 500mg every 12				5 days
ND new	hours				
onsolidation	Detients who amelia				(provided afebrile and
TI OHOSE A Tay	Patients who smoke				clinically stable for 48
	and/or with				hours. Otherwise 7 da
	co-morbidities				P
	Co-amoxiclav PO				Most patients can be
	875/125mg every 8				treated with oral
	hours/IV 1.2g every 8				antibiotics
	hours				
	+				
	Ol:41i DO (I) / if				
	Clarithromycin PO (IV if				
	NPO) 500mg every 12				
	hours				
	Severe <u>CURB-65</u> Score				
	Co-amoxiclav IV 1.2g	CefTRIAXone IV 2g	Levofloxacin PO (IV if N	PO) 500mg every 12 hours	Duration
	every 8 hours	every 24 hours	Avoid levofloxacin in pre	gnancy or breastfeeding.	7 davs
	 	 -	Discuss with Micro/ID.		
			prolonged QT interval.		Longer courses may b
	Clarithromycin PO (IV if	Clarithromycin PO (IV if			indicated according to
	NPO) 500mg every 12	NPO) 500mg every 12			clinical judgement
	hours	hours			.,,
					e.g. if <i>Legionella</i>
					pneumophila,
					Staphylococcus aureu
					or Gram-negative bac
					suspected or confirme
					Consider addition of
					steroids for those
					requiring Non Invasive
					Ventilation (NIV)/
					Mechanical Ventilation
					(MV) in consultation w
	I				Resp/ID.

Galway: GAPP - Galway Antimicrobial Prescribing Policy / Guidelines (GAPP) - Last Updated: Nov. 7, 2024, 11:53 a.m., printed: Nov. 23, 2024, 11:09 a.m.
page 2 of 4

Refs:

- 1. Community-Acquired Pneumonia. The New England Journal of Medicine. 2023. 389:632-41.
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care 2019;200(7):e45–e67
- 3. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. <u>JAMA</u> Intern Med 2016;176(9):1257-1265
- 4. British Thoracic Society Guidelines for the management of community acquired pneumonia in adults. Annotated CAP Guideline 2015.

Chronic Obstructive Pulmonary Disease (COPD)

Empiric Antibiotics for COPD			
Infection		In penicillin allergy See penicillin hypersensitivity section for further information	Comment
COPD Exacerbation	Amoxicillin PO 1g every 8 hours	Clarithromycin PO 500mg every 12 hours	Duration
without infiltrate	every 8 hours (Consider Co-amoxiclav PO 875/125mg every 8 hours for severe infection)	OR	5 days (provided afebrile and clinically stable for 48 hours. Otherwise 7 days)


Refs:

1. HSE. Infective exacerbation of COPD. Antibiotic prescribing ie Accessed April 2024

Hospital Acquired Pneumonia

Hospital Acquired Pneumonia

- 1. Pneumonia should be treated as hospital acquired if onset from 5 days after hospital admission or within 14 days of discharge.
- 2. Nursing home patients presenting for admission to hospital with pneumonia should be treated as CAP and NOT automatically treated with piperacillin/tazobactam unless history of antibiotic resistant organisms or within 14 days of discharge from hospital.
- $3. \ \ \text{The regimens below may NOT cover Multi-drug Resistant Organisms (MDRO) in all cases. } \textbf{See note on } \underline{\textbf{MDRO}} \ .$
- 4. Intensive care and immunosuppressed patients should be discussed with Microbiology or Infectious Diseases.



Galway: GAPP - Galway Antimicrobial Prescribing Policy / Guidelines (GAPP) - Last Updated: Nov. 7, 2024, 11:53 a.m., printed: Nov. 23, 2024, 11:09 a.m.

page 3 of 4

Refs:

1. American Thoracic Society/Infectious Diseases Society of America. Management of adults with hospital-acquired and ventilator-associated pneumonia Clin Infect Dis 2016;63:e61-111

Pneumocystis jirovecii pneumonia (PJP)

Pneumocystis jirovecii pneumonia (PJP)

- 1. Discussion with Microbiology or Infectious Diseases recommended.
- 2. Co-trimoxazole in high dosage is the treatment of choice for mild, moderate and severe PJP.
- 3. For **moderate to severe disease** (Pa02 ≤9kPa on room air), **high dose steroids** should be co-administered with anti-pneumocystis therapy and should be discontinued before anti-pneumocystis therapy is complete: Prednisolone 40mg PO twice daily for 5 days, then 40mg once daily for 5 days, then 20mg once daily to complete a total of 14 to 21 days (depending on duration of PJP treatment).

nfection	1 st Line	2 nd line	Comment
JP	Co-trimoxazole* IV/PO 120mg/kg/ day	Severe disease:	Duration (ID or Micro consult
	divided into a 6 to 8 hourly dosing regimen	Pentamidine IV 4mg/kg once daily	recommended):
	e.g. 30mg/kg every 6 hours*	Only to be used if intolerant or unresponsive to co- trimoxazole. Risk	Non-HIV infected: 14 -21 days HIV infected: 21 days
	e.g. 70kg patient: 70x120 = 8,400mg	of significant adverse events including	1
		severe hypotension and	
	2,100mg every 6 hours (round dose to	· · · · · · · · · · · · · · · · · · ·	
	nearest 480mg=1920mg)	Non-severe disease:	
	In severe disease consider oral switch at same dose when clinically	Atovaquone	
	improving.	OR	
	In mild to moderate disease consider oral route from outset.	Dapsone + Trimethoprim	
	olar roule mann outcou	OR	
		Clindamycin + Primaquine	
		Contact Microbiology or Infectious	
		Diseases or Pharmacy for advice and dosing.	

Refs:

- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection. Accessed 23rd April 2024.
- 2. Pneumocystis jirovecii pneumonia. Catherinot et al. Infect Dis Clin North Am 2009;24:107-138

Galway: GAPP - Galway Antimicrobial Prescribing Policy / Guidelines (GAPP) - Last Updated: Nov. 7, 2024, 11:53 a.m., printed: Nov. 23, 2024,
11:09 a.m.
page 4 of 4